| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5266123
Max Phase: Preclinical
Molecular Formula: C26H21Cl2N3O3S
Molecular Weight: 526.45
Associated Items:
Representations
Canonical SMILES: COc1ccc2c(c1)c(CC(=O)NC(=S)Nc1ccc(Cl)cc1)c(C)n2C(=O)c1ccc(Cl)cc1
Standard InChI: InChI=1S/C26H21Cl2N3O3S/c1-15-21(14-24(32)30-26(35)29-19-9-7-18(28)8-10-19)22-13-20(34-2)11-12-23(22)31(15)25(33)16-3-5-17(27)6-4-16/h3-13H,14H2,1-2H3,(H2,29,30,32,35)
Standard InChI Key: CKVDXPYUDXZVST-UHFFFAOYSA-N
Associated Targets(non-human)
Cyclooxygenase-2 1953 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 526.45 | Molecular Weight (Monoisotopic): 525.0681 | AlogP: 6.01 | #Rotatable Bonds: 5 |
| Polar Surface Area: 72.36 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
| #RO5 Violations: 2 | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: 9.24 | CX Basic pKa: | CX LogP: 6.11 | CX LogD: 6.11 |
| Aromatic Rings: 4 | Heavy Atoms: 35 | QED Weighted: 0.31 | Np Likeness Score: -1.42 |
References
| 1. Ahmadi M, Bekeschus S, Weltmann KD, von Woedtke T, Wende K.. (2022) Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors., 13 (5.0): [PMID:35685617] [10.1039/d1md00280e] |
Source
Source(1):